Publications:405
Josep Llovet, MD
About Me
Josep M. Llovet, MD, PhD is Director of the Liver Cancer Program and Professor of Medicine (Division of Liver Diseases) at the Icahn School of Medicine at Mount Sinai. He is also Professor of Medicine-Hepatic Oncology at the University of Barcelona and Professor of Research-ICREA in the Liver Unit at IDIBAPS-Hospital Clínic of Barcelona.
Dr. Llovet was the Founder and has been President of the International Liver Cancer Association. He has chaired and contributed to the development of more than 10 guidelines related to clinical management and clinical trial design in liver cancer. He was Chairman of the European Association for the Study of Liver Disease (EASL)-Clinical Practice Guidelines 2012, President of the American Association for the Study of Liver Diseases Special Interest Group in Hepatobiliary Neoplasia, and a member of the Educational Committee of EASL. He has published more than 345 articles in peer-reviewed journals (with more than 145,000 citations) and more than 55 book chapters, and has delivered more than 675 lectures. He is Editor in Chief of JHEP Reports and has been Associate/Senior Editor of Journal of Hepatology and Clinical Cancer Research. Dr. Llovet has been a Top-1% cited researcher in Clarivate Analytics since 2014.
Dr. Llovet has devoted his career to studying the pathogenesis and treatment of liver cancer. He received the American Association for Cancer Research-Landon International Award (2009) and the International Hans Popper Award (2012), and has received competitive funding from the National Cancer Institute, European Commission, and other grantors for more than 100 research projects.
Language
English
Position
PROFESSOR | Medicine, Liver Diseases
Research Topics
Cancer, Liver
Video
Education
MD, University of Barcelona
, Hospital Germans Trias i Pujol
PhD, Autonomous University of Barcelona
Awards
2015
AASLD Fellowship Award
American Association for the Study of the Liver Diseases
2014
Director - ILCA School of Liver Cancer
2014
Highly Cited Researchers
Thomson Reuters
2013
Josep Trueta award, Best scientist
Acadèmia Ciències Mèdiques de Catalunya-Barcelona.
2012
International Hans Popper Award 2012, for excellence in basic and experimental Hepatology. Falk Symposium, Mainz
• Recognition as one of “The WORLD’s Most Influential Scientific Minds 2015”.
Thomson Reuters
Research
A.-Establishment of sorafenib as standard of care in patients with advanced HCC (Llovet, New Engl J Med 2008). This breakthrough achievement establishes sorafenib as first line treatment for advanced HCC, and represents the first identification of survival advantages with systemic treatments. Identified by Nature Medicine as the most cited paper in oncology 2008-2010. Adopted by American (AASLD) and European (EASL-EORTC) guidelines of management of HCC.
B.-Establishment of chemoembolization as standard of care in patients with intermediate HCC. Evidence-based establishment through randomized controlled trials [Llovet, Lancet 2002] and meta-analysis [Llovet, Hepatology 2003] of chemoembolization as standard of care in patients with intermediate HCC. Adopted by American (AASLD) and European (EASL-EORTC) guidelines of management of HCC.
C.-Guidelines of management of HCC and ICC: Chair of EASL-EORTC Guidelines, 2012 (J Hepatol, 2012; Eur J Cancer 2012), and co-author of ILCA Guidelines of management of ICC (J Hepatol, 2014)
D.-Clinical trials. Dr. Llovet has participated as principal investigator in several international clinical trials that aimed to assess the tyrosine-kinase inhibitor sorafenib as adjuvant treatment after resection or ablative therapy (STORM trial. 1200 patients, 220 centers), sorafenib in combination with chemoembolization (SPACE trial. 400 patients, 120 centers), sorafenib in combination with erlotinib versus sorafenib at first line of treatment (SEARCH trial. 1000 patients), and the VEGFR1, VEGFR2, VEGFR3 and FGFR multi tyrosine-kinase inhibitor brivanib as a second line in patients who failed in the treatment with sorafenib (BRISK trial. 350 patients). Some of these clinical trials were published: Bruix J, J Hepatol. 2012; Llovet JM, J Clin Oncol. 2013; Llovet JM, Clin Cancer Res. 2012; Raoul JL, J Hepatol. 2012; Zhu AX, JCO 2014; Burrel M, J Hepatol. 2012; Forner A, J Hepatol. 2012; Roayaie S, Hepatology. 2013.
Publications
Selected Publications
- Histone methyl-transferase G9a inhibition boosts the efficacy of immune checkpoint inhibitors in experimental hepatocellular carcinoma. Elena Adan-Villaescusa, Borja Castello-Uribe, Iker Uriarte, Eva Santamaria, Roberto Barbero, Miriam Belzunce, Amaya López-Pascual, Maria Ujue Latasa, Jasmin Elurbide, Emiliana Valbuena-Goiricelaya, Agavni Mesropian, Guillem Cano-Segarra, Ana Hernández de Sande, Lorenzo Nevi, Simone Carotti, Umberto Vespasiani-Gentilucci, Felipe Prosper, Antonio Pineda-Lucena, Bruno Sangro, Josepmaria Argemi, Pedro Berraondo, Pablo Sarobe, Albert Gris-Oliver, Roser Pinyol, Josep M. Llovet, Maria Arechederra, Carmen Berasain, Alexis Cocozaki, Veronica Gibaja, Matias A. Avila, Maite G. Fernandez-Barrena. Cell Reports Medicine
- Hallmarks of liver cancer: Therapeutic implications. Josep M. Llovet, Roser Pinyol, Silvia Affo, Mark Yarchoan, Gregory J. Gores, Robin Kate Kelley, Scott W. Lowe, Daniela Sia, Augusto Villanueva. Cell
- Effective therapeutic targeting of CTNNB1-mutant hepatoblastoma with WNTinib. Ugne Balaseviciute, Júlia Huguet-Pradell, Jordi Abril-Fornaguera, Albert Gris-Oliver, Alex Rialdi, Elisa Fernández-Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho-Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet. Molecular Oncology
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Llovet during 2025 and/or 2026. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services
Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership- Bayer Healthcare Pharmaceuticals
- Bristol-Myers Squibb
- Merck & Co., Inc.
- Guidepoint
- Boehringer Ingelheim, Ltd.
- Eisai, Inc.
- Bluejay Therapeutics, Inc.
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.